{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:35:51Z","timestamp":1770348951605,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.urolonc.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:44:03Z","timestamp":1727729043000},"page":"61.e11-61.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-4662","authenticated-orcid":false,"given":"Kerem","family":"Teke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00fcmer","family":"Baltac\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Akg\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahad\u0131r","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"T\u00fcrkeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozan","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U\u011fur","family":"Y\u00fcceta\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcven","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Bolat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"\u0130zol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Alp","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saadettin","family":"Eski\u00e7orap\u00e7i","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.09.006_bib0001","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0002","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2023.10.010","article-title":"The 2023 European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: a critical appraisal","volume":"85","author":"Hensley","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0004","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euo.2018.02.007","article-title":"Neoadjuvant dose-dense gemcitabine and cisplatin in muscle-invasive bladder cancer: results of a phase 2 trial","volume":"1","author":"Anari","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0006","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0007","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sjodahl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clgc.2021.07.011","article-title":"Histological variants of urothelial carcinoma predict no response to neoadjuvant chemotherapy","volume":"20","author":"Leite","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0011","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","article-title":"Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer","volume":"36","author":"Iyer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00345-022-04187-w","article-title":"Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3\/4 or cN+ bladder cancer","volume":"41","author":"Wagner","year":"2023","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.09.006_bib0013","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3390\/jcm9061962","article-title":"Survival outcomes of patients with pathologically proven positive lymph nodes at time of radical cystectomy with or without neoadjuvant chemotherapy","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0014","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2017.2374","article-title":"Adjuvant chemotherapy vs observation for patients with adverse pathologic features at radical cystectomy previously treated with neoadjuvant chemotherapy","volume":"4","author":"Seisen","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0015","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00345-016-1825-3","article-title":"Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy","volume":"34","author":"Zargar-Shoshtari","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0016","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/tau-20-571","article-title":"Adjuvant chemotherapy in patients with locally advanced bladder cancer after neoadjuvant chemotherapy and radical cystectomy: a systematic review and pooled analysis","volume":"10","author":"Cai","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0017","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/0895-4356(95)00510-2","article-title":"Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy","volume":"48","author":"Concato","year":"1995","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0018","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1186\/s12885-023-11572-0","article-title":"Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0021","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s12094-023-03277-4","article-title":"Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience","volume":"26","author":"Serrano","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0022","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0023","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00345-023-04478-w","article-title":"Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes","volume":"41","author":"Aydh","year":"2023","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.09.006_bib0024","article-title":"Neoadjuvant chemotherapy for different stages of muscle-invasive bladder cancer: a systematic review and meta-analysis","author":"Liu","year":"2022","journal-title":"Disease Markers"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ijc.31833","article-title":"Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer","volume":"144","author":"Hermans","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0026","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.juro.2015.11.024","article-title":"A retrospective analysis of the effect on survival of time from diagnosis to neoadjuvant chemotherapy to cystectomy for muscle invasive bladder cancer","volume":"195","author":"Park","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.09.006_bib0027","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924006471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:15:50Z","timestamp":1732706150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924006471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1078143924006471"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of risk factors for cancer-specific survival in neoadjuvant chemotherapy nonresponsive disease of muscle-invasive bladder cancer: A multicentre study from the Turkish Urooncology Association Bladder Tumor study group","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}